Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Trovagene Inc (TROV)

Trovagene Inc (TROV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,552
  • Shares Outstanding, K 4,922
  • Annual Sales, $ 380 K
  • Annual Income, $ -16,460 K
  • 60-Month Beta 0.90
  • Price/Sales 32.29
  • Price/Cash Flow N/A
  • Price/Book 1.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.64
  • Growth Rate Est. (year over year) +37,940.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.43 +4.12%
on 06/20/19
3.46 -26.88%
on 06/07/19
-0.57 (-18.39%)
since 05/24/19
3-Month
2.43 +4.12%
on 06/20/19
5.83 -56.60%
on 04/01/19
-1.33 (-34.46%)
since 03/22/19
52-Week
2.43 +4.12%
on 06/20/19
9.65 -73.78%
on 03/08/19
-2.33 (-47.94%)
since 06/22/18

Most Recent Stories

More News
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD(TM) in Models of Colorectal Cancer

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
LPBC : 9.5000 (-4.52%)
Trovagene: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Tuesday reported a loss of $3.9 million in its first quarter.

TROV : 2.53 (-0.78%)
Trovagene Announces First Quarter 2019 Results and Highlights

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
New Gene Therapies Hold Out Promise for Patients

Gene therapies are gaining growing attention within the medical sector.

TROV : 2.53 (-0.78%)
ONCE : 101.91 (-3.01%)
NVS : 92.80 (+0.34%)
DYAI : 6.17 (-7.77%)
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
LPBC : 9.5000 (-4.52%)
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)
Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias,...

TROV : 2.53 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade TROV with:

Business Summary

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue...

See More

Key Turning Points

2nd Resistance Point 2.66
1st Resistance Point 2.60
Last Price 2.53
1st Support Level 2.48
2nd Support Level 2.42

See More

52-Week High 9.65
Fibonacci 61.8% 6.89
Fibonacci 50% 6.04
Fibonacci 38.2% 5.19
Last Price 2.53
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar